Autres langues Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
3,56 ^USD	-2,73 %		-6,56 %	-17,78 %

02/06	Puma Biotechnology, Inc. annonce la présentation des résultats d'une étude de phase II sur l'alisertib dans le cancer du sein métastatique résistant à l'endocrinien (Tbcrc 041)	CI
17/05	Pfizer obtient 107,5 millions de dollars d'AstraZeneca dans un procès sur les brevets de médicaments anticancéreux aux États-Unis	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Puma Biotechnology : Corporate Presentation	03/06
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer	03/06
Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	02/06
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)	02/06
Puma Biotechnology to Join Russell 3000 Index	28/05
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting	23/05
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	17/05
Puma Biotech: Q1 Earnings Snapshot	02/05
Puma Biotechnology Reports First Quarter Financial Results	02/05
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	02/05
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	18/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	04/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	03/04
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	20/03
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology : Corporate Presentation	06/03
Puma Biotech: Q4 Earnings Snapshot	29/02
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Puma Biotechnology, Inc.

Actions

PBYI

US74587V1070

Autres langues

Filtres